Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer

Molecular and Cellular Endocrinology

Volumn 340, Issue 2, 2011, Pages 161-167

  Ito, Kiyoshi ^a   Utsunomiya, Hiroki ^a   Niikura, Hitoshi ^a   Yaegashi, Nobuo ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

17 Hydroxysteroid dehydrogenases; Aromatase inhibitor; Endocrine therapy; Endometrial carcinoma; Estrogen; Ovarian carcinoma

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; AROMATASE; AROMATASE INHIBITOR; CISPLATIN; ESTROGEN; ESTROGEN SULFOTRANSFERASE; GESTAGEN; HYDROXYSTEROID DEHYDROGENASE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID; STERYL SULFATASE;

CANCER HORMONE THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; HORMONAL REGULATION; HUMAN; LOW DRUG DOSE; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS;

EID: 79960281507     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2010.11.023     Document Type: Review

References (74)

1. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
2. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349:458-461.
3. Berstein L., Kovalevskij A., Zimarina T., Maximov S., Gershfeld E., Vasilyev D., Baisheva S., Baymakhasheva A., Thijssen J.H. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. J. Steroid Biochem. Mol. Biol. 2005, 95:71-74.
4. Berstein L.M., Kvatchevskaya J.O., Poroshina T.E., Kovalenko I.G., Tsyrlina E.V., Zimarina T.S., Ourmantcheeva A.F., Ashrafian L., Thijssen J.H. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J. Cancer Res. Clin. Oncol. 2004, 130:687-693.
5. Berstein L.M., Tchernobrovkina A.E., Gamajunova V.B., Kovalevskij A.J., Vasilyev D.A., Chepik O.F., Turkevitch E.A., Tsyrlina E.V., Maximov S.J., Ashrafian L.A., Thijssen J.H. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J. Cancer Res. Clin. Oncol. 2003, 129:245-249.
6. Bonney R.C., Scanlon M.J., Jones D.L., Reed M.J., Anderson M.C., James V.H. The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer. Eur. J. Cancer Clin. Oncol. 1986, 22:953-961.
7. Bonofiglio D., Cione E., Qi H., Pingitore A., Perri M., Catalano S., Vizza D., Panno M.L., Genchi G., Fuqua S.A., Andò S. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am. J. Pathol. 2009, 175:1270-1280.
8. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., Smyth J.F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 2002, 8:2233-2239.
9. Bulun S.E., Lin Z., Imir G., Amin S., Demura M., Yilmaz B., Martin R., Utsunomiya H., Thung S., Gurates B., Tamura M., Langoi D., Deb S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol. Rev. 2005, 57:359-383.
10. Casey M.L., MacDonald P.C., Andersson S. 17-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progentin regulation of gene expression in human endometrium. J. Clin. Invest. 1994, 94:2135-2141.
11. Ceil F.S., Shuldiner A.R. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr. Diab. Rep. 2002, 2:179-185.
12. Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F., Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72:23-27.
13. Cunat S., Rabenoelina F., Daurès J.P., Katsaros D., Sasano H., Miller W.R., Maudelonde T., Pujol P. Aromatase expression in ovarian epithelial cancers. J. Steroid Biochem. Mol. Biol. 2005, 93:15-24.
14. Dufort I., Rheault P., Huang X.F., Soucy P., Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999, 140:568-574.
15. Evans T.R., Kaye S.B. Retinoids: present role and future potential. Br. J. Cancer 1999, 80:1-8.
16. Foster P.A., Woo L.W., Potter B.V., Reed M.J., Purohit A. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 2008, 149:4035-4042.
17. Gast M.J., Sims H.F., Murdock G.L., Gast P.M., Strauss A.W. Isolation and sequencing of a complementary deoxyribonucleic acid clone encoding human placental 17 beta-estradiol dehydrogenase: identification of the putative cofactor binding site. Am. J. Obstet. Gynecol. 1989, 161:1726-1731.
18. Graham J.D., Clarke C.L. Physiological action of progesterone in target tissues. Endocr. Rev. 1997, 18:502-519.
19. Ito K., Suzuki T., Moriya T., Utsunomiya H., Sugawara A., Konno R., Sato S., Sasano H. Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase. J. Clin. Endocrinol. Metab. 2001, 86:2721-2727.
20. Ito K. In situ estrogen metabolism and synthesis in endometrium and breast. Acta Obstet. Gynaec. Jpn. 2005, 57:1819-1827.
21. Ito K., Utsunomiya H., Suzuki T., Saitou S., Akahira J., Okamura K., Yaegashi N., Sasano H. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol. Cell. Endocrinol. 2006, 248:136-140.
22. Inoue M., Sobue T., Tsugane S. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: data from a large-scale population-based cohort study - The JPHC Study. Cancer Causes Control 2004, 15:671-680. for the JPHC Study Group.
23. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., Thun M.J. Cancer statistics 2004. CA Cancer J. Clin. 2004, 54:8-29. American Cancer Society.
24. Kaga K., Sasano H., Harada N., Ozaki M., Sato S., Yajima A. Aromatase in human common epithelial ovarian neoplasms. Am. J. Pathol. 1996, 149:45-51.
25. Kaku T., Yoshikawa H., Tsuda H., Sakamoto A., Fukunaga M., Kuwabara Y., Hataeg M., Kodama S., Kuzuya K., Sato S., Nishimura T., Hiura M., Nakano H., Iwasaka T., Miyazaki K., Kamura T. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001, 167:39-48.
26. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol. 1989, 28:561-566.
27. Kelsey J.L. A case control study of cancer of the endometrium. Am. J. Epidemiol. 1982, 116:333-342.
28. Koeffer H.P. Peroxisome proliferators-activated receptor gamma and carcinomas. Clin. Cancer Res. 2003, 9:1-9.
29. Kudelka A.P., Freedman R.S., Edwards C.L., Lippman S.M., Tornos C.S., Krakoff I.H., Kavanagh J.J. Metastatic adenocarcinoma of the endometrium treated with 13-cis-retinoic acid plus interferon-alpha. Anticancer Drugs 1993, 4:335-337.
30. Li Y.F., Hu W., Fu S.Q., Li J.D., Liu J.H., Kavanagh J.J. Aromatase inhibitors in ovarian cancer: is there a roleŽ. Int. J. Gynecol. Cancer 2008, 18:600-614.
31. Luu-The V., Dufort I., Pelletier G., Labrie F. Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol. Cell. Endocrinol. 2001, 171:77-82.
32. Luu The V., Labrie C., Zhao H.F., Couet J., Lachance Y., Simard J., Leblanc G., Cote J., Berube D., Gagne R. Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5′-termini in human placenta. Mol. Endocrinol. 1989, 3:1301-1309.
33. Lukanova A., Lundin E., Micheli A., Arslan A., Ferrari P., Rinaldi S., Krogh V., Lenner P., Shore R.E., Biessy C., Muti P., Riboli E., Koenig K.L., Levitz M., Stattin P., Berrino F., Hallmans G., Kaaks R., Toniolo P., Zeleniuch-Jacquotte A. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int. J. Cancer 2004, 108:425-432.
34. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W., Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer 2004, 14:650-658.
35. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
36. Matsumoto M., Yamaguchi Y., Seino Y., Hatakeyama A., Takei H., Niikura H., Ito K., Suzuki T., Sasano H., Yaegashi N., Hayashi S. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr. Relat. Cancer 2008, 15:451-463.
37. Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y., Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 2001, 94:685-689.
38. Naitoh K., Honjo H., Yamamoto T., Urabe M., Ogino Y., Yasumura T., Nambara T. Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. J. Steroid Biochem. 1989, 33:1049-1054.
39. Ota K., Ito K., Suzuki T., Saito S., Tamura M., Hayashi S., Okamura K., Sasano H., Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin. Cancer Res. 2006, 12:4200-4208.
40. Papi A., Rocchi P., Ferreri A.M., Guerra F., Orlandi M. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol. Rep. 2009, 21:1083-1089.
41. Pasqualini J.R., Chetrite G.S. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J. Steroid Biochem. Mol. Biol. 1999, 69:287-292.
42. Pasqualini J.R. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 2004, 1654:123-143.
43. Pelletier G., Luu-The V., Tetu B., Labrie F. Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem. Cytochem. 1999, 47:731-738.
44. Potischman N., Hoover R.N., Brinton L.A., Siiteri P., Dorgan J.F., Swanson C.A., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D., Persky V., Lurain J.R. Case-control study of endogenous steroid hormones and endometrial cancer. J. Natl. Cancer Inst. 1996, 88:1127-1135.
45. Rao B.R., Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12:14-26.
46. Rose P.G., Brunetto V.L., VanLe L., Bell J., Walker J.L., Lee R.B. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2000, 78:212-216.
47. Sasano H., Harada N. Intratumoral aromatase in human breast, endometrial and ovarian malignancy. Endocr. Soc. 1998, 19:593-607.
48. Sasano H., Suzuki T., Takeyama J., Utsunomiya H., Ito K., Ariga N., Moriya T. 17-beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology. Oncology 2000, 59:5-12.
49. Sasano H., Sato S., Ito K., Yajima A., Nakamura J., Yoshihama M., Ariga K., Anderson T.J., Miller W.R. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr. Relat. Cancer 1999, 6:197-204.
50. Segawa T., Shozu M., Murakami K., Kasai T., Shinohara K., Nomura K., Ohno S., Inoue M. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin. Cancer Res. 2005, 11:2188-2194.
51. Sherman M.E., Sturgeon S., Brinton L.A., Potischman N., Kurman R.J., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 1997, 10:963-968.
52. Shiozawa T., Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int. J. Clin. Oncol. 2006, 11:13-21.
53. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662. WHIMS Investigators.
54. Smuc T., Rupreht R., Sinkovec J., Adamski J., Rizner T.L. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol. Cell. Endocrinol. 2006, 248:114-117.
55. Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R., Nafussi A.A., Rye T., Rye R., Stewart M., McCurdy J., Mano M., Reed N., McMahon T., Vasey P., Gabra H., Langdon S.P. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 2007, 13:3617-3622.
56. Suzuki T., Moriya T., Ariga N., Kaneko C., Kanazawa M., Sasano H. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer 2000, 82:518-523.
57. Suzuki T., Darnel A.D., Akahira J.I., Ariga N., Ogawa S., Kaneko C., Takeyama J., Moriya T., Sasano H. 5Alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J. Clin. Endocrinol. Metab. 2001, 86:2250-2257.
58. Suzuki T., Nakata T., Miki Y., Kaneko C., Moriya T., Ishida T., Akinaga S., Hirakawa H., Kimura M., Sasano H. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003, 63:2762-2770.
59. Takahashi-Shiga N., Utsunomiya H., Miki Y., Nagase S., Kobayashi R., Matsumoto M., Niikura H., Ito K., Yaegashi N. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Clin. Cancer Res. 2009, 15:6028-6034.
60. Tanabe K., Utsunomiya H., Tamura M., Niikura H., Takano T., Yoshinaga K., Nagase S., Suzuki T., Ito K., Matsumoto M., Hayashi S., Yaegashi N. Expression of retinoic acid receptors in human endometrial carcinoma. Cancer Sci. 2008, 99:267-271.
61. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., Soper J.T., Given F.T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 1999, 17:1736-1744.
62. Thoma D.B. Do hormones cause cancerŽ. Cancer 1984, 53:595-604.
63. Ushijima K., Yahata H., Yoshikawa H., Konishi I., Yasugi T., Saito T., Nakanishi T., Sasaki H., Saji F., Iwasaka T., Hatae M., Kodama S., Saito T., Terakawa N., Yaegashi N., Hiura M., Sakamoto A., Tsuda H., Fukunaga M., Kamura T. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J. Clin. Oncol. 2007, 25:2798-2803.
64. Utsunomiya H., Suzuki T., Kaneko C., Takeyama J., Nakamura J., Kimura K., Yoshihama M., Harada N., Ito K., Konno R., Sato S., Okamura K., Sasano H. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J. Clin. Endocrinol. Metab. 2001, 86:3436-3443.
65. Utsunomiya H., Ito K., Suzuki T., Kitamura T., Kaneko C., Nakata T., Niikura H., Okamura K., Yaegashi N., Sasano H. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin. Cancer Res. 2004, 10:5850-5856.
66. Utsunomiya H., Suzuki T., Ito K., Moriya T., Konno R., Sato S., Yaegashi N., Okamura K., Sasano H. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin. Endocrinol. 2003, 58:696-703.
67. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985, 45:2900-2906.
68. Vermeulen-Meiners C., Poortman J., Haspels A.A., Thijssen J.H. The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J. Steroid Biochem. 1986, 24:1073-1078.
69. Vihko P., Harkonen P., Soronen P., Torn S., Herrala A., Kurkela R., Pulkka A., Oduwole O., Isomaa V. 17 Beta-hydroxysteroid dehydrogenases - their role in pathophysiology. Mol. Cell. Endocrinol. 2004, 215:83-88.
70. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 2007, 106:461-468.
71. Watanabe K., Sasano H., Harada N., Ozaki M., Niikura H., Sato S., Yajima A. Aromatase in human endometrial carcinoma and hyperplasia immunohistochemical, in situ hybridization, and biochemical studies. Am. J. Pathol. 1995, 146:491-500.
72. Wu L., Einstein M., Geissler W.M., Chan H.K., Elliston K.O., Andersson S. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 1993, 268:12964-12969.
73. Wu Y., Guo S.W. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil. Steril. 2009, 91:2142-2147.
74. Yang S., Fang Z., Gurates B., Tamura M., Miller J., Ferrer K., Bulun S.E. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol. Endocrinol. 2001, 15:2093-2105.